Article

A pilot study on the use of amikacin in neonates: Who should be monitored for ototoxicity?

Published in: Southern African Journal of Infectious Diseases
Volume 30 , issue 3 , 2015 , pages: 72–76

DOI: 10.1080/23120053.2015.1074432

Author(s): Deirdré Engler Department of Pharmacy, South Africa , Natalie Schellack Department of Pharmacy, South Africa , Alida Naude Discipline of Speech- Language Pathology and Audiology, South Africa , Andries Gous Department of Pharmacy, South Africa

Keywords: amikacin , neonates , ototoxicity , pharmacokinetics

Download full text Get new issue alerts

Abstract

Background: Aminoglycosides (AGs) cause irreversible hearing loss. The toxic effects of AGs are dose dependent and correlate with increasing drug serum concentrations.

« Nocardia mastoiditis in an African child

Experiences in the implementation of provider-initiated counselling and testing and linkage to HIV services at urban public sector health facilities in KwaZulu-Natal »